F. Hoffmann-La Roche AG: clinical-trial pipeline
F. Hoffmann-La Roche AG is the sponsor of 2,147 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 226 are not yet finished and 18 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials226
Phase 2/3 and 3598
Countries98
New in 90 days18
Trials by phase
| Phase | Trials |
|---|---|
| Phase 3 | 586 |
| Phase 1 | 450 |
| Phase 2 | 408 |
| Not applicable | 405 |
| Phase 4 | 208 |
| Phase 1/2 | 77 |
| Phase 2/3 | 12 |
| Early phase 1 | 1 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 1,672 |
| Terminated | 201 |
| Active, not recruiting | 124 |
| Recruiting | 82 |
| Withdrawn or not authorised | 43 |
| Not yet recruiting | 20 |
| Unknown | 3 |
| Suspended or halted | 2 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 894 |
| Immunology and rheumatology | 276 |
| Infectious disease and vaccines | 250 |
| Gastroenterology and liver | 217 |
| Haematology | 130 |
| Metabolic and endocrine (diabetes, obesity) | 126 |
| Neurology | 104 |
| Nephrology and urology | 88 |
| Rare and genetic diseases | 74 |
| Respiratory | 61 |
| Ophthalmology | 54 |
| Cardiovascular | 48 |
Countries
| Country | Trials |
|---|---|
| United States | 925 |
| Spain | 716 |
| France | 674 |
| Italy | 625 |
| Germany | 623 |
| United Kingdom | 563 |
| Canada | 473 |
| Poland | 470 |
| Australia | 421 |
| Belgium | 344 |
| Brazil | 340 |
| South Korea | 325 |
| Netherlands | 302 |
| Mexico | 288 |
| Russia | 287 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-23 | New trial posted | A Multicenter, Dose-Escalation and Dose-Finding, First-In-Human Study to Investigate Safe… |
| 2026-10-22 | New trial posted | A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participant… |
| 2026-10-20 | New trial posted | A Study of RO7821657 in Participants With Solid Tumors |
| 2026-09-29 | New trial posted | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Ef… |
| 2026-09-29 | New trial posted | A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Particip… |
| 2026-09-28 | New trial posted | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants Wit… |
| 2026-09-28 | New trial posted | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants Wit… |
| 2026-09-28 | New trial posted | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants Wit… |
| 2026-09-24 | New trial posted | Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Ch… |
| 2026-09-22 | New trial posted | A Study to Assess the Effect of Subcutaneous Injection Site on the Pharmacokinetics of Pe… |
| 2026-09-18 | New trial posted | Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting… |
| 2026-09-18 | New trial posted | A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure P… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT05704361 | A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous R… | Phase 1 | Active, not recruiting | Belgium, Canada, Germany, Spain +8 |
| NCT04963296 | A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus | Phase 3 | Active, not recruiting | Argentina, Brazil, Czechia, Spain +10 |
| NCT04873362 | A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for… | Phase 3 | Active, not recruiting | Austria, Australia, Belgium, Bulgaria +27 |
| NCT03523858 | A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis | Phase 3 | Active, not recruiting | United Arab Emirates, Bosnia & Herzegovina, Brazil, Canada +20 |
| NCT03100149 | A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Di… | Phase 2 | Active, not recruiting | Austria, Germany, Spain, France +1 |
| 2023-505222-34-00 | An Open-Label, Multi-Center, Phase Ib/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus A… | Phase 1/2 | Active, not recruiting | Belgium, Denmark, Spain, Italy |
| NCT04546009 | A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole… | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +25 |
| 2023-504264-41-00 | A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and… | Phase 1/2 | Recruiting | Czechia, Germany, Denmark, Spain +4 |
| NCT05593094 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Fact… | Phase 1/2 | Active, not recruiting | Australia, Spain, France, United Kingdom +3 |
| 2023-506611-17-00 | A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTI… | Phase 1/2 | Recruiting | France |
| NCT05686551 | GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo… | Phase 2 | Active, not recruiting | Argentina, Austria, Australia, Canada +11 |
| 2023-507236-20-00 | A Phase Ib/II, Open-Label, Multicenter Study with a Non-Randomized Stage Evaluating the Safety, Pharmacokinet… | Phase 1/2 | Active, not recruiting | Spain, France |
| 2023-506899-27-00 | A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Co… | Phase 3 | Active, not recruiting | Belgium, Germany, Denmark, Spain +2 |
| 2023-506861-76-00 | A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Ad… | Phase 3 | Active, not recruiting | Austria, Germany, Denmark, Spain +6 |
| NCT05789082 | A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combinatio… | Phase 1/2 | Recruiting | Argentina, Australia, Belgium, Brazil +14 |
| 2023-504027-78-00 | A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With… | Phase 2 | Active, not recruiting | Germany, Denmark, Spain, France +3 |
| NCT04432584 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants… | Phase 3 | Active, not recruiting | Belgium, Brazil, Czechia, Germany +19 |
| 2023-507500-31-00 | A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatme… | Phase 2/3 | Active, not recruiting | Belgium, Germany, Spain, France +2 |
| NCT03424005 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or… | Phase 1/2 | Recruiting | Australia, Germany, Spain, France +5 |
| NCT02320435 | A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Ho… | Phase 3 | Active, not recruiting | Brazil, China, Costa Rica, Germany +11 |
| NCT02650401 | Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Prim… | Phase 1/2 | Active, not recruiting | Canada, China, Germany, Spain +5 |
| NCT05181618 | A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Mode… | Phase 4 | Active, not recruiting | Brazil, Canada, Germany, Spain +7 |
| NCT04434092 | A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal No… | Phase 3 | Active, not recruiting | Argentina, Brazil, China, Germany +19 |
| 2023-507728-22-00 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneou… | Phase 1 | Recruiting | Belgium, Denmark, Spain, Italy +1 |
| 2023-505865-94-00 | A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cel… | Phase 1/2 | Active, not recruiting | Belgium, Germany, Spain, France +1 |
Hiring for clinical development
F. Hoffmann-La Roche AG has 49 open jobs with a clinical, regulatory, safety, biostatistics or medical-affairs title on its own career sites.
Website: roche.com. All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "F. Hoffmann-La Roche AG clinical trials: 226 open, 598 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/roche-com/, data as of 2026-10-25.